



PSubstitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT  
(Use several sheets if necessary)

ATTY DOCKET NO.

11591-008-999

APPLICATION NO.

10/590,892;  
U.S. Natl. Stage of  
PCT/DK2005/000140

APPLICANT:

Hansen et al.

FILING DATE:

February 28, 2005

ART UNIT:

CONF. NO.:

3750

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS*		DOCUMENT NUMBER	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
.	A01	4,939,164	07/03/1990	Wierzbicki et al.	
	A02	5,075,336	12/24/1991	Czernecki et al.	
.	A03	5,128,367	07/07/1992	Wierzbicki et al.	
	A04	5,851,556	12/22/1998	Breton et al.	
	A05	5,856,356	01/05/1999	Tsouderos et al.	
	A06	2002/018748	2/14/2002	Satz Roseanne et al.	
	A07	2004/0059134	03/25/2004	Vaysse-Ludot et al.	
	A08	2004/0059135	03/25/2004	Vaysse-Ludot et al.	
	A09	2004/0063972	04/01/2004	Vaysse-Ludot et al.	
	A10	2005/0013877	01/20/2005	Jellum et al.	
	A11	2005/0142211	06/30/2005	Wenz	
	A12	2006/0275503	12/07/2006	Hansen et al.	
	A13	2006/0216358	09/28/2006	Hansen et al.	
	A14	2006/0122274	06/08/2006	Hansen et al.	

## FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS*		Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
						YES	NO
	B01	DE 102 25 420	12/24/2003	Sonatix GmbH (w/ English Abstract)			
	B02	EP 0 381 445	08/08/1990	Vissam Research Dev. Co. of the Hebrew University of Jerusalem			
	B03	EP 0 404 558	12/27/1990	Vissam Research Dev. Co. of the Hebrew University of Jerusalem			
	B04	EP 0 415 850	03/06/1991	Adir Et Compagnie (w/ English Abstract)			
	B05	EP 0 813 869	12/29/1997	Adir Et Compagnie (w/ English Abstract)			
	B06	WO 98/35657	08/20/1998	Collagenex Pharmaceuticals, Inc.			
	B07	WO 99/34772	07/15/1999	Enamelon, Inc.			

EXAMINER  
NYI-3992386v1

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for Form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.  11591-008-999	APPLICATION NO. 10/590,892; U.S. Natl. Stage of PCT/DK2005/000140
	APPLICANT: Hansen et al.	
	FILING DATE: February 28, 2005	ART UNIT:    CONF. NO.: 3750

FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS*		Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
						YES	NO
	B08	WO/00/01692	01/13/2000	Smithkline Beecham PLC			
	B09	WO 03/028742	04/10/2003	Santo Solve AS			
	B10	WO/03/043626	05/30/2003	Gramineer International AB			
	B11	WO 2004/084920	10/07/2004	Santosolve AS			
	B12	WO 2004/098617	11/18/2004	Nordic Bone A/S			
	B13	WO 2004/098618	11/18/2004	Nordic Bone A/S			
	B14	WO 2004/098619	11/18/2004	Nordic Bone A/S			
	B15	WO 2005/049038	06/02/2005	Medesis Pharma SA			
	B16	WO 2005/082385	09/09/2005	Osteologix A/S			
	B17	WO 2005/123098	12/29/2005	Osteologix A/S			
	B18	WO 2005/123192	12/29/2005	Osteologix A/S			
	B19	WO 2005/123193	12/29/2005	Osteologix A/S			
	B20	EP-B 0 415 850	03/06/1991	Adir et Compagnie			
	B21	WO 03/028742	4/10/2003	Santosolve A/S			
	B22	EP 0 737 471 A	10/16/1996	L'Oreal			
	B23	EP 390 456 A2	10/03/1990	Beechamp Group			
	B24	GB 990,957	5/05/1965	Murray William Rosenthal			

NON PATENT LITERATURE DOCUMENTS <i>(include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book ,magazine, journal, etc.), date, page(s)s, volume, publisher, city and/or country where published., etc.)</i>		
EXAMINER'S INITIALS*		
	C01	[No author named] "Calcium, phosphorus, and strontium metabolism in infants," Nutr Rev 1969 Sep;27(9):254-6
	C02	[No author named] "Influence of stable strontium on bone growth and strength," Nutr Rev 1959 Oct;17:312-3
	C03	ALBERTSSON et al., "An x-ray and neutron study of a gel-brown phase of calcium malonate dihydrate," Acta Cryst 1978;B34:2737-43
	C04	ALDA et al., "Transport of calcium, magnesium and strontium by human serum proteins," Rev Esp Fisiol 1985 Jun;41(2):145-9

NYI-3992386v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute for Form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO.
	11591-008-999	10/590,892; U.S. Natl. Stage of PCT/DK2005/000140
	APPLICANT: Hansen et al.	
	FILING DATE: February 28, 2005	ART UNIT:    CONF. NO.: 3750

**NON PATENT LITERATURE DOCUMENTS** (include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume, publisher, city and/or country where published., etc.)

EXAMINER'S INITIALS*		
	C05	AMMANN et al., "Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats," J Bone Miner Res 2004 Dec;19(12):2012-20
	C06	ANDERSON et al., "Solubility of various forms of strontium titanate in lungs: in vitro and in vivo studies," Health Phys 1999 Jun;76(6):628-34
	C07	ANDERSON et al., "Strontium retention as a function of age in the dog," Rad Res 1968;34:153-69
	C08	APPLETON, "Changes in the plasma electrolytes and metabolites of the rat following acute exposure to sodium fluoride and strontium chloride," Arch Oral Biol 1995 Apr;40(4):265-8
	C09	APOSTOAEI, "Absorption of strontium from the gastrointestinal tract into plasma in healthy human adults," Health Phys 2002 Jul;83(1):56-65
	C10	ARDISSINO et al., "No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure," Kidney Int 2000 Sep;58(3):981-8
	C11	ARMBRECHT et al., "Effect of 1,25-dihydroxyvitamin D3 on intestinal calcium absorption in strontium-fed rats," Arch Biochem Biophys 1979 Feb;192(2):466-73
	C12	ASHRAFI et al., "Pre- and posteruptive effects of low doses of strontium on dental caries in the rat," Caries Res 1980;14(5):341-6
	C13	BADER et al., "The effect of hydroxylamine, mercaptans, divalent metals and chelators on (Na <sup>+</sup> plus K <sup>+</sup> )-ATPase. A possible control mechanism," Biochim Biophys Acta 1970 Mar 18;198(3):583-93
	C14	BARBARA et al., "Normal matrix mineralization induced by strontium ranelate in MC3T3-E1 osteogenic cells," Metabolism 2004 Apr;53(4):532-7
	C15	BARRY et al., "The hemodynamic effects of strontium chloride in the intact dog," Proc Soc Exp Biol Med 1972 Oct;141(1):52-8
	C16	BARTO et al., "Sensitive method for analysis of strontium in human and animal plasma by graphite furnace atomic absorption spectrophotometry," Clin Chem 1995 Aug;41(8 Pt 1):1159-63
	C17	BERGER et al., "[On mechanism of strontium deposition in bone tissue]," Acta Histochem 1965 Dec 24;22(5):298-308, (in German, w/ English Abstract)
	C18	BEST et al., "Strontium ions induce production of thromboxane B2 and secretion of 5-hydroxytryptamine in washed human platelets," Biochem Pharmacol 1981 Mar 15;30(6):635-7
	C19	BIANCHI et al., "No difference in intestinal strontium absorption after an oral or an intravenous 1,25(OH)2D3 bolus in normal subjects. For the European Study Group on Vitamin D in children with renal failure," J Bone Miner Res 1999 Oct;14(10):1789-95
	C20	BLUMSOHN, "Stable strontium absorption as a measure of intestinal calcium absorption: comparison with the double-radiotracer calcium absorption test," Clin Sc 1994;87:363-8
	C21	BOIVIN et al., "Effects of bisphosphonates on matrix mineralization," J Musculoskelet Neuronal Interact 2002 Dec;2(6):538-43
	C22	BOIVIN et al., "Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration," J Bone Miner Res 1996 Sep;11(9):1302-11
	C23	BRANDI, "New perspectives in the prevention and treatment of glucocorticoid-induced osteoporosis," Clin and Experimental Rheum 2000;18(5):S74-8

NYI-3992386v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute for Form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO.
	11591-008-999	10/590,892; U.S. Natl. Stage of PCT/DK2005/000140
	APPLICANT: Hansen et al.	
	FILING DATE: February 28, 2005	ART UNIT:    CONF. NO.: 3750

**NON PATENT LITERATURE DOCUMENTS** (include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume, publisher, city and/or country where published., etc.)

EXAMINER'S INITIALS*		
	C24	BRIGGMAN et al., "The crystal structures of calcium malonate dihydrate and strontium malonate," Acta Cryst (1977);B333:1900-06
	C25	BROWN et al., "Is the calcium receptor a molecular target for the actions of strontium on bone?," Osteoporosis Int 2003;14(3):S25-34
	C26	BUEHLER et al., "Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis)," Bone 2001 Aug;29(2):176-9
	C27	BURGUERA et al., "Age and sex-related calcium and strontium concentrations in different types of human bones," Trace Elements and Electrolytes 2002;19(3):143-51
	C28	BURTON et al., "Discrimination between strontium and calcium in their passage from diet to the bone of adult man," Nature 1962 Mar 3;193:846-7
	C29	CABRERA et al., "Strontium and bone," J Bone Miner Res 1999 May;14(5):661-8
	C30	CANALIS et al., "The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro," Bone 1996 Jun;18(6):517-23
	C31	CARAFOLI, "In vivo effect of uncoupling agents on the incorporation of calcium and strontium into mitochondria and other subcellular fractions of rat liver," J Gen Physiol 1967 Aug;50(7):1849-64
	C32	CHRISTOPFFERSEN et al., "Effects of strontium ions on growth and dissolution of hydroxyapatite and on bone mineral detection," Bone 1997 Jan;20(1):47-54
	C33	COHN et al., "Kinetics of strontium and calcium skeletal metabolism in the rat," Riv Patol Nerv Ment 1966 Aug;87(4):79-83
	C34	COLE et al., "The toxicity of strontium and calcium," J Pharmacol Exp Ther 1941;404(71):1-5
	C35	CREGER et al., "Strontium and bone development under conditions of suboptimal vitamin D," Calc Tissue Res 1971;8(1):83-6
	C36	DAHL et al., "Incorporation and distribution of strontium in bone," Bone 2001 Apr;28(4):446-53
	C37	DELANNOY et al., "Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice," Metabolism 2002 Jul;51(7):906-11
	C38	D'HAESE et al., "Increased bone strontium levels in hemodialysis patients with osteomalacia," Kidney Int 2000 Mar;57(3):1107-14
	C39	D'HAESE et al., "Measurement of strontium in serum, urine, bone, and soft tissues by Zeeman atomic absorption spectrometry," Clin Chem 1997 Jan;43(1):121-8
	C40	DOGGRELL, "Present and future pharmacotherapy for osteoporosis," Drugs Today (Barc) 2003 Aug;39(8):633-57
	C41	EISENBERG, "Effect of intravenous phosphate on serum strontium and calcium," N Engl J Med 1970 Apr 16;282(16):889-92
	C42	EISENBERG, "Effects of androgens, estrogens and corticoids on strontium kinetics in man," J Clin Endocrinol Metab 1966 May;26(5):566-72
	C43	FERRARO et al., "The effect of strontium chloride upon alveolar bone," J Periodontol 1980 Jun;51(6):345-7.
	C44	FOREMAN et al., "Proceedings: Activation of anaphylactic histamine release by calcium and strontium ions," Br J Pharmacol 1972 Feb;44(2):326P

NYI-3992386v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute for Form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO.
	11591-008-999	10/590,892; U.S. Natl. Stage of PCT/DK2005/000140
	APPLICANT: Hansen et al.	
	FILING DATE: February 28, 2005	ART UNIT:    CONF. NO.: 3750

**NON PATENT LITERATURE DOCUMENTS** (include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume, publisher, city and/or country where published., etc.)

EXAMINER'S INITIALS*		
	C45	FUJITA et al., "Retention and excretion of strontium-85 in mice, rats and rabbits--extrapolation to long-term retention in humans," Health Phys 1965 Apr;11:271-81
	C46	GASTINEAU et al., "Metabolic studies of a patient with osteoporosis and diabetes mellitus: effects of testosterone enanthate and strontium lactate," Mayo Med Ventures 1960 March;35(2):105-11
	C47	GHOSH et al., "Clastogenic activity of strontium chloride on bone marrow cells in vivo," Biol Trace Elem Res 1990 Apr;25(1):51-6
	C48	GIBBONS et al., "The passage of calcium and strontium across the gut of the anaesthetized goat," J Physiol 1972 Apr;222(2):397-406
	C49	GRUDEN, "The effect of lactose and iron on strontium absorption," Experientia 1984 Sep 15;40(9):941-2
	C50	GRYNPAS et al., "Effects of low doses of strontium on bone quality and quantity in rats," Bone 1990;11(5):313-9
	C51	GRYNPAS et al., "Strontium increases vertebral bone volume in rats at a low dose that does not induce detectable mineralization defect," Bone 1996 Mar;18(3):253-9
	C52	GUSMANO et al., "Evaluation of the parameters of strontium metabolism in the rat as a function of age," Radiat Res 1968 Mar;33(3):540-53
	C53	GUTTERIDGE et al., "Delayed strontium absorption in post-menopausal osteoporosis and osteomalacia," Clin Sci 1968 Apr;34(2):351-63
	C54	HAHN, "Strontium is a potent and selective inhibitor of sensory irritation," Dermatol Surg 1999 Sep;25(9):689-94
	C55	HARRISON et al., "Bone metabolism in rats, studied with stable strontium," J Endocrinol 1960 Nov;21:191-6
	C56	HARRISON et al., "On the mechanism of skeletal fixation of strontium. Parts I and II," Archives BioChem 1959;80:97-113
	C57	HARRISON et al., "The metabolism of strontium in man," Clin Sci (Lond) 1955 Nov;14(4):681-95
	C58	HENDRIX et al., "Competition between calcium, strontium, and magnesium for absorption in the isolated rat intestine," Clin Chem 1963 Dec;12:734-44
	C59	HIBBINS, "Strontium and strontium compounds," Kirk-Othmer Encyclopedia of Chemical Technology, 4 <sup>th</sup> ed. 1997;22:947-55
	C60	HOUSTON et al., "The systemic treatment of bone metastases," Clin Orthop Relat Res 1995 Mar;(312):95-104
	C61	International Search Report of International Application No. PCT/DK2004/000326, mailed 2/23/2005
	C62	International Search Report of International Application No. PCT/DK2004/00327, mailed 2/14/2005
	C63	International Search Report of International Application No. PCT/DK2004/000328, mailed 2/4/2005
	C64	International Search Report of International Application No. PCT/DK2005/000710, mailed 2/7/2006
	C65	International Search Report of International Application No. PCT/DK2005/000140, mailed July 26, 2005
	C66	JOHNSON et al., "The exchangeability of calcium and strontium of bone in vitro," Calcif Tissue Res. 1970;6(2):103-12
	C67	JOHNSON et al., "The incorporation and removal of large amounts of strontium by physiologic mechanisms in

NYI-3992386v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute for Form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO.
	11591-008-999	10/590,892; U.S. Natl. Stage of PCT/DK2005/000140
	APPLICANT: Hansen et al.	
	FILING DATE: February 28, 2005	ART UNIT:    CONF. NO.: 3750

**NON PATENT LITERATURE DOCUMENTS** (include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume, publisher, city and/or country where published., etc.)

EXAMINER'S INITIALS*		
		mineralized tissues," Calcif Tissue Res 1968;2(3):242-52
	C68	KROES et al., "Short-term toxicity of strontium chloride in rats," Toxicology 1977 Feb;7(1):11-21
	C69	LEHNERDT, [On the question of replacing calcium in the bone system by strontium Second Report. Feeding of strontium to suckling animals, the influence of strontium on the bone system of the weaned young] 215-47 (in German, w/ English translation)
	C70	LEEUWENKAMP et al., "Human pharmacokinetics of orally administered strontium," Calcif Tissue Int 1990 Sep;47(3):136-41
	C71	LLOYD, "Relative binding of strontium and calcium in protein and non-protein fractions of serum in the rabbit," Nature. 1968 Jan 27;217(126):355-6
	C72	LOESER et al., "A study of the toxicity of strontium and comparison with other cations employed in therapeutics," J Lab Clin Med 1930;15:35-41
	C73	MacDONALD et al., "The skeletal deposition of non-radioactive strontium," J Biol Chem 1951 Jan;188(1):137-43
	C74	MALTBY et al., "Exchange of potassium and strontium in adult bone," Am J Physiol 1982 Apr;242(4):H705-12
	C75	MARIE P.J., "Effects of strontium on bone tissue and bone cells," Therapeutic Uses of Trace Elements, edited by Neve et al., Plenum Press, NY, 1996 pp. 277-282
	C76	MARIE et al., "An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats," J Bone Miner Res 1993 May;8(5):607-15
	C77	MARIE et al., "Effect of low doses of stable strontium on bone metabolism in rats," Miner Electrolyte Metab 1985;11(1):5-13
	C78	MARIE et al., "Histomorphometry of bone changes in stable strontium therapy," Environ. Health 1985;19:193-208
	C79	MARIE et al., "Mechanisms of action and therapeutic potential of strontium in bone," Calcif Tissue Int 2001 Sep;69(3):121-9
	C80	MARIE et al., Short-term effects of fluoride and strontium on bone formation and resorption in the mouse," Metabolism. 1986 Jun;35(6):547-51
	C81	MATSUMOTO, "Effect of strontium chloride on bone resorption induced by prostaglandin E2 in cultured bone," Arch Toxicol 1988;62(2-3):240-1
	C82	McCASLIN et al., "The effect of strontium lactate in the treatment of osteoporosis," Staff Meeting at the Mayo Clinic 1959;34(13):329-34
	C83	MEUNIER et al., "Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis," Osteoporos Int. 2003;14 Suppl 3:S66-76
	C84	MEUNIER et al., "Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial," J Clin Endocrinol Metab. 2002 May;87(5):2060-6
	C85	MEUNIER et al., "The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis," N Engl J Med 2004 Jan 29;350(5):459-68
	C86	MOROHASHI et al., "Effects of strontium on calcium metabolism in rats. II. Strontium prevents the increased rate of bone turnover in ovariectomized rats" Jpn J Pharmacol 1995 Jun;68(2):153-9
	C87	MÜLLER et al., "The course in time of the strontium retention in man," Health Phys 1968 Apr;14(4):285-92

NYI-3992386v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute for Form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO.
	11591-008-999	10/590,892; U.S. Natl. Stage of PCT/DK2005/000140
	APPLICANT: Hansen et al.	
	FILING DATE: February 28, 2005	ART UNIT:    CONF. NO.: 3750

<b>NON PATENT LITERATURE DOCUMENTS</b> <i>(include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book ,magazine, journal, etc.), date, page(s)s, volume, publisher, city and/or country where published., etc.)</i>		
EXAMINER'S INITIALS*		
	C88	NEWTON et al., "Metabolism of Ca and Sr in late adult life," Health Phys 1990 Oct;59(4):433-42
	C89	NIELSEN et al., "Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry," J Clin Densitom 1999 Winter;2(4):371-9
	C90	PALMER et al., " Discrimination in intestinal absorption of strontium and calcium," Proc Soc Exp Biol Med 1961 Nov;108:296-300
	C91	PALMER et al., "Strontium-calcium interrelationships in the growing rat," Am J Physiol 1964 Sep;207:561-6
	C92	PRICE et al., "Hydrothermal crystallisation and x-ray structure of anhydrous strontium oxalate," Polyhedron 1999;18:2499-2503
	C93	REGINSTER et al., "Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial," Osteoporos Int 2002 Dec;13(12):925-31
	C94	Reginster et al., "Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies," Osteoporos Int 2003;14 Suppl 3:S56-65
	C95	REGINSTER et al., " Strontium ranelate: a new paradigm in the treatment of osteoporosis," Drugs Today (Barc). 2003 Feb;39(2):89-101
	C96	REGINSTER," Strontium ranelate in osteoporosis," Curr Pharm Des 2002;8(21):1907-16
	C97	REID et al., "The assessment of intestinal calcium absorption using stable strontium," Calcif Tissue Int. 1986 May;38(5):303-5
	C98	SCHMIDBAUR et al., "Metal ion binding by amino acids: strontium and barium L-aspartate trihydrate SR/BA(L-ASP) 3h20," Chemische Berichte, Verlas Chemie GMBH 1990;123(8):1599-602
	C99	SCHMIDBAUR et al., "Preparation and crystal structures of magnesium, strontium, and barium l-glutamate hydrates," Chem Ber 1989;122:1433-8
	C100	SCHOENBERG, "Extent of strontium substitution for calcium in hydroxyapatite," Biochim Biophys Acta. 1963 Jul 23;75:96-103
	C101	SCHROEDER et al., "Trace metals in man: strontium and barium," J Chronic Dis 1972 Sep;25(9):491-517
	C102	SCHROOTEN et al., "Strontium causes osteomalacia in chronic renal failure rats," Kidney Int 1998 Aug;54(2):448-56
	C103	SHORR et al., "The usefulness of strontium as an adjuvant to calcium in the remineralization of the skeleton in man," Bull Hosp Joint Dis 1952 Apr;13(1):59-66
	C104	SKORYNA, "Effects of oral supplementation with stable strontium," Can Med Assoc J 1981 Oct 1;125(7):703-12
	C105	SORBERA et al., "Strontium ranelate treatment and prevention of osteoporosis bone resorption inhibitor bone formation stimulant," Drug Fut 2003 Apr;28(4):328-35
	C106	STOREY, "Calcium and strontium changes in bone associated with continuous administration of stable strontium to rats," Arch Biochem Biophys 1968 Mar 20;124(1):575-81
	C107	STOREY, "Strontium 'rickets': bone, calcium and strontium changes," Australas Ann Med 1961 Aug;10:213-22
	C108	SVENSSON et al., "The effect of strontium and manganese on freshly isolated chondrocytes," Acta Pathol Microbiol Immunol Scand [A] 1985 May;93(3):115-20
	C109	TEN BOLSCHER et al., "Oestrogen has no short-term effect on intestinal strontium absorption in healthy

NYI-3992386v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute for Form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO.
	11591-008-999	10/590,892; U.S. Natl. Stage of PCT/DK2005/000140
	APPLICANT: Hansen et al.	
	FILING DATE: February 28, 2005	ART UNIT:    CONF. NO.: 3750

**NON PATENT LITERATURE DOCUMENTS** (include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume, publisher, city and/or country where published., etc.)

EXAMINER'S INITIALS*		
		postmenopausal women," Clin Endocrinol (Oxf) 1999 Mar;50(3):387-92
	C110	TEN BOLSCHER et al., "Strontium as a marker for intestinal calcium absorption: the stimulatory effect of calcitriol," Clin Chem 2000;46(2):248-51
	C111	URIU et al., "Uncoupling between bone formation and resorption in ovariectomized rats with chronic cadmium exposure," Toxicol Appl Pharmacol 2000 May 1;164(3):264-72
	C112	WARREN et al., "Metabolic balances of strontium in man," Clin Orthop Relat Res 1976 Jun;(117):307-20
	C113	BARLOW, "Strontium and Osteoporosis," Journal of the British Menopause Society; March 2003 March; 9(1) 7
	C114	ROBINSON N.A. & YEO J.F. "Bispho[honates – A word of caution," Ann. Acad Med. Singapore, 2004; 33 (4 Suppl):48-49
	C115	GREENBERG, M.S. "Intravenous bisphosphonates and osteonecrosis," Oral Surg. Oral Med Oral Pathol Oral Radiol Endod., 2004, Vol. 98, pp. 259-60
	C116	REGINSTER, J.Y., "Stronium renaletein osteoporosis," Curr. Pharm. Des. 2002, Vol. 8, pp. 1907-16
	C117	ASTRAND, J. and ASSPENBERG P, " Systemic alendronate prevents resorption of necrotic bone during revascularizaton. A bone chamber study in rats," BMC Musculoskelet Disord. 2002, Vol. 3:19, pp. 1-5
	C118	BROUSSE C., "Osteoarticular complications of corticotherapy," Hepato-Gastro, 2000 France, Vol. 7(3), pp. 173-178
	C119	"Depistage Isotopique de l'Osteonecrose," Nouvelle Presse Medicale, Press Medicale, Paris, Fr., Vol. 2(9), p. 583
	C120	BEERS, BERKOW (EDS): "The Merck manual of diagnosis and therapy," 17 <sup>th</sup> Edn, 1999, Merck Research Laboratories, pp. 453-454
	C121	SOERDJBALIE-MAIKOE, VIDYA et al., "Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton," European Journal of Nuclear Medicine and Molecular Imaging, Vol. 29(4), pp. 494-498, 2002

NYI-3992386v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	